

Granulomatosis with Polyangiitis Treatment Market Report and Forecast 2024-2032

Market Report | 2024-07-19 | 200 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$4999.00
- Five User License \$5999.00
- Corporate License \$6999.00

Report description:

Granulomatosis with Polyangiitis Treatment Market Report and Forecast 2024-2032

The granulomatosis with polyangiitis treatment market size is expected to grow at a CAGR of 4.90% during the forecast period of 2024-2032, driven by the increasing improvements in diagnostic technologies.

Granulomatosis with Polyangiitis Treatment Market Analysis

The granulomatosis with polyangiitis (GPA) treatment market involves addressing a rare autoimmune disease that primarily affects the blood vessels and organs, causing inflammation. This market analysis explores the drivers, challenges, and future opportunities impacting this specialised healthcare segment.

Market Drivers:

- ☐ Increasing Awareness and Diagnosis: There is a growing awareness of GPA and similar diseases, leading to earlier and more accurate diagnoses. This has been facilitated by advances in medical imaging and diagnostic technologies.
- ☐ Advancements in Treatment Options: The development of new medications and therapies, including biologics and targeted therapies, has significantly improved treatment outcomes. This progress encourages ongoing investment and interest in the market.
- ☐ Rising Healthcare Expenditure: Global increases in healthcare spending enable more comprehensive and sophisticated treatment approaches, including those required for complex conditions like GPA.
- ☐ Supportive Regulatory Environment: Regulatory bodies are increasingly supportive of orphan drug development, which benefits diseases like GPA that have a relatively small patient population but a high unmet medical need.

Market Challenges:

- ☐ High Cost of Treatment: The treatments for GPA, particularly newer biologic therapies, are often expensive, which can limit accessibility for patients without adequate insurance or in less developed healthcare systems.
- ☐ Limited Patient Population: As a rare disease, the small number of patients with GPA can restrict market size and reduce the commercial incentive for pharmaceutical companies to develop new treatments.
- ☐ Complexity of Disease Management: GPA requires a multidisciplinary approach to treatment, involving various specialists. Coordinating this care can be challenging and costly.
- ☐ Adverse Effects of Treatment: Many current treatments, while effective, carry the risk of significant side effects, which can affect

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

patient compliance and overall treatment efficacy.

Future Opportunities:

- Emergence of Personalised Medicine: Advances in genetics and disease understanding could lead to more personalised treatment approaches that are more effective and have fewer side effects.
- Expansion into New Markets: Increasing global healthcare access provides opportunities to introduce effective GPA treatments into emerging markets, expanding the patient base and improving outcomes worldwide.
- Innovative Drug Development: The continued focus on orphan drug development, supported by incentives like tax breaks and market exclusivity, encourages pharmaceutical companies to invest in innovative treatments for rare diseases like GPA.
- Collaborative Research Initiatives: Collaborations between academic institutions, research organisations, and pharmaceutical companies can accelerate the development of new treatments and share the financial risks involved in targeting a rare disease.

Granulomatosis with Polyangiitis Treatment Market Trends

The global market for granulomatosis with polyangiitis (GPA) treatment is influenced by several trends that reflect evolving treatment paradigms, regulatory landscapes, and technological advancements. Here are some key trends currently shaping this market:

-□Increased Use of Biologic Therapies

Biologics are becoming increasingly prominent in the treatment of GPA due to their ability to target specific parts of the immune system involved in the disease process. These therapies offer the potential for more effective management with fewer side effects compared to traditional cytotoxic drugs.

-□Growth of Personalised Medicine

Personalised medicine is gaining traction in the treatment of rare diseases like GPA. Genetic and biomarker research is helping to tailor treatments to individual patient profiles, which can improve outcomes and minimise adverse effects.

-□Expansion of Orphan Drug Designations

Regulatory agencies are offering various incentives for orphan drug development, including tax credits, user fee waivers, and market exclusivity. This has encouraged pharmaceutical companies to invest in developing drugs for rare diseases such as GPA, despite the smaller market size.

-□Advancements in Diagnostic Technologies

Improvements in diagnostic technologies, including advanced imaging and serological tests, are enabling earlier and more accurate diagnosis of GPA. Early diagnosis is crucial for effective disease management and can significantly affect the treatment market by increasing the number of patients eligible for therapy.

-□Global Health Initiatives and Funding

Increased funding from global health initiatives focused on rare diseases is supporting research and development activities, as well as patient access to necessary treatments. This funding is crucial for driving forward new treatments and expanding access in underserved regions.

-□Collaborative Research Efforts

There is a growing trend towards collaboration between academic institutions, healthcare providers, and pharmaceutical companies. These partnerships aim to share knowledge, resources, and funding to accelerate the pace of innovation in GPA treatment.

These trends indicate a dynamic and evolving market landscape, where ongoing research and development are critical to addressing the complex challenges associated with treating granulomatosis with polyangiitis. The focus on more targeted and patient-specific therapies is particularly promising, potentially leading to better management of the disease and improved patient outcomes.

Granulomatosis with Polyangiitis Treatment Market Segmentation

Market Breakup by Drug Class

- Steroids
- Immunosuppressant

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The granulomatosis with polyangiitis treatment market is segmented by drug class into steroids and immunosuppressants. Steroids, as a cornerstone in GPA management, address acute phases of inflammation and are driven by their rapid efficacy. Immunosuppressants, including newer biologics, are increasingly preferred for long-term management due to their ability to modulate immune responses more selectively, reducing long-term side effects associated with steroids. The shift towards immunosuppressants is likely to drive market growth, particularly as ongoing research expands their applications and improves safety profiles. Both segments are poised to contribute significantly to market expansion during the forecast period, with immunosuppressants expected to see particularly robust growth due to advancements in targeted therapy.

Market Breakup by Route of Administration

- Oral
- Intravenous

The granulomatosis with polyangiitis (GPA) treatment market is segmented by the route of administration into oral and intravenous methods. Oral treatments, favored for their convenience and suitability for long-term management, drive the market with their ease of use and patient compliance. On the other hand, intravenous (IV) treatments are crucial for severe cases of GPA where rapid and effective drug delivery is needed. IV administration is particularly important for biologics and other potent immunosuppressants, which are increasingly used in GPA management. Looking forward, IV treatments are expected to experience significant growth due to their effectiveness in acute management and the development of more advanced biologic treatments. Both segments are vital for the market, each serving critical roles in different phases of disease management and patient care settings, thereby driving overall market growth in the forecast period.

Market Breakup by Distribution Channel

- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies

The granulomatosis with polyangiitis treatment market is segmented by distribution channel into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies dominate due to their direct link to patient care and the necessity of managing acute treatments, especially for intravenous medications. Retail pharmacies provide accessibility for ongoing, maintenance medications and are expanding with improvements in supply chain efficiencies. Online pharmacies are rapidly growing, driven by consumer convenience and the increasing digitalisation of healthcare services. This segment is poised to significantly boost market growth during the forecast period, as more patients turn to online platforms for ease and privacy in obtaining their medications. Together, these channels ensure widespread drug availability, supporting the overall growth of the GPA treatment market.

Market Breakup by Region

- United States
- EU-4 and the United Kingdom
 - ?□ Germany
 - ?□ France
 - ?□ Italy
 - ?□ Spain
 - ?□ United Kingdom
- Japan
- China

The granulomatosis with polyangiitis treatment market is segmented across key regions, each presenting unique dynamics. The United States leads due to advanced healthcare infrastructure and regulatory support, while the EU-4 and the United Kingdom

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

collectively exhibit strong potential with comprehensive healthcare systems. Germany stands out for its medical research and pharmaceutical innovation, while France, Italy, and Spain benefit from established healthcare frameworks. Japan represents a significant market with high standards of care, and China shows promise with its rapidly expanding healthcare infrastructure. These regions collectively contribute to the global market's growth, driven by demographic factors, healthcare policies, and economic conditions, with developed regions maintaining steady growth and emerging markets showing rapid increases in demand.

Granulomatosis with Polyangiitis Treatment Market Competitive Landscape

In the competitive landscape of the granulomatosis with polyangiitis treatment market, key players such as Genentech, Inc., GlaxoSmithKline plc., Sonoma Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Antares Pharma, Medac Pharma, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Sanofi, and Orion Corporation engage in various market activities. These include mergers and acquisitions to strengthen portfolios and expand market reach, research initiatives to develop innovative treatments, frequent product introductions to address unmet needs, and partnerships with other stakeholders to enhance research capabilities or distribution networks. These activities collectively shape the competitive landscape, driving innovation and market growth in the granulomatosis with polyangiitis treatment market.

Key Questions Answered in the Report

- ?□What is the current and future performance of the granulomatosis with polyangiitis treatment market?
- ?□What are the main challenges facing the granulomatosis with polyangiitis treatment market?
- ?□What are the key drivers of the granulomatosis with polyangiitis treatment market?
- ?□What emerging trends are shaping the future of the granulomatosis with polyangiitis treatment market?
- ?□How do intravenous treatments improve management of severe granulomatosis with polyangiitis cases?
- ?□How does increased funding from global health initiatives benefit research on rare diseases?
- ?□What are the common strategies used by key players in the granulomatosis with polyangiitis treatment market?

Key Benefits for Stakeholders

- ?□The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the granulomatosis with polyangiitis treatment market from 2017-2032.
- ?□The research report provides the latest information on the market drivers, challenges, and opportunities in the granulomatosis with polyangiitis treatment market.
- ?□The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- ?□Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyse the level of competition within the granulomatosis with polyangiitis treatment industry and its attractiveness.
- ?□The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

Table of Contents:

- 1□Preface
- 1.1□Objectives of the Study
- 1.2□Key Assumptions
- 1.3□Report Coverage - Key Segmentation and Scope
- 1.4□Research Methodology
- 2□Executive Summary
- 3□Granulomatosis with Polyangiitis Treatment Market Overview: 8 Major Market
- 3.1□Granulomatosis with Polyangiitis Treatment Market Historical Value (2017-2023)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

3.2	Granulomatosis with Polyangiitis Treatment Market Forecast Value (2024-2032)
4	Vendor Positioning Analysis
4.1	Key Vendors
4.2	Prospective Leaders
4.3	Niche Leaders
4.4	Disruptors
5	Granulomatosis with Polyangiitis Treatment Market: Disease Overview
5.1	Guidelines and Stages
5.2	Pathophysiology
5.3	Screening and Diagnosis
5.4	Therapy Pathway
6	Patient Profile
6.1	Patient Profile Overview
6.2	Patient Psychology and Emotional Impact Factors
6.3	Risk Assessment and Therapy Success Rate
7	Granulomatosis with Polyangiitis Treatment Market Epidemiology Scenario and Forecast - 8 Major Markets
7.1	8MM Epidemiology Scenario Overview (2017-2032)
7.1.1	Prevalence, by Country
7.1.1.1	U.S.
7.1.1.2	U.K.
7.1.1.3	EU4
7.1.1.4	India
7.1.1.5	Japan
7.1.2	Mortality by Country
7.1.2.1	U.S.
7.1.2.2	U.K.
7.1.2.3	EU4
7.1.2.4	India
7.1.2.5	Japan
7.1.3	Treatment Seeking Rate by Country
7.1.3.1	U.S.
7.1.3.2	U.K.
7.1.3.3	EU4
7.1.3.4	India
7.1.3.5	Japan
8	Granulomatosis with Polyangiitis Treatment Market Landscape: 8 Major Market*
8.1	Granulomatosis with Polyangiitis Treatment Market: Developers Landscape
8.1.1	Analysis by Year of Establishment
8.1.2	Analysis by Company Size
8.1.3	Analysis by Region
8.2	Granulomatosis with Polyangiitis Treatment Market: Product Landscape
8.2.1	Analysis by Drug Class
8.2.2	Analysis by Route of Administration
9	Granulomatosis with Polyangiitis Treatment Market Challenges and Unmet Needs
9.1	Therapy Pathway Challenges
9.2	Compliance and Drop-Out Analysis
9.3	Awareness and Prevention Gaps

- 10□Cost of Therapy□
- 11□Granulomatosis with Polyangiitis Treatment: Market Dynamics
 - 11.1□Market Drivers and Constraints
 - 11.2□SWOT Analysis
 - 11.2.1□Strengths
 - 11.2.2□Weaknesses
 - 11.2.3□Opportunities
 - 11.2.4□Threats
 - 11.3□PESTEL Analysis
 - 11.3.1□Political
 - 11.3.2□Economic
 - 11.3.3□Social
 - 11.3.4□Technological
 - 11.3.5□Legal
 - 11.3.6□Environment
 - 11.4□Porter's Five Forces Model
 - 11.4.1□Bargaining Power of Suppliers
 - 11.4.2□Bargaining Power of Buyers
 - 11.4.3□Threat of New Entrants
 - 11.4.4□Threat of Substitutes
 - 11.4.5□Degree of Rivalry
 - 11.5□Key Demand Indicators
 - 11.6□Key Price Indicators
 - 11.7□Industry Events, Initiatives, and Trends
 - 11.8□Value Chain Analysis
- 12□Granulomatosis with Polyangiitis Treatment Market Segmentation: 8 Major Markets
 - 12.1□Granulomatosis with Polyangiitis Treatment Market by Drug Class
 - 12.1.1□Market Overview
 - 12.1.2□Steroids
 - 12.1.3□Immunosuppressant
 - 12.1.4□Others
 - 12.2□Granulomatosis with Polyangiitis Treatment Market by Route of Administration
 - 12.2.1□Market Overview
 - 12.2.2□Oral
 - 12.2.3□Intravenous
 - 12.2.4□Others
 - 12.3□Granulomatosis with Polyangiitis Treatment Market by Distribution Channel
 - 12.3.1□Market Overview
 - 12.3.2□Hospital Pharmacy
 - 12.3.3□Retail Pharmacy
 - 12.3.4□Online Pharmacy
 - 12.4□Granulomatosis with Polyangiitis Treatment Market by Region
 - 12.4.1□Market Overview
 - 12.4.2□United States
 - 12.4.3□EU-4 and the United Kingdom
 - 12.4.3.1□Germany
 - 12.4.3.2□France

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.4.3.3 Italy
- 12.4.3.4 Spain
- 12.4.3.5 United Kingdom
- 12.4.4 Japan
- 12.4.5 India
- 13 United States Granulomatosis with Polyangiitis Treatment Market (2017-2032)
- 13.1 United States Granulomatosis with Polyangiitis Treatment Market Historical Value (2017-2023)
- 13.2 United States Granulomatosis with Polyangiitis Treatment Market Forecast Value (2024-2032)
- 13.3 United States Granulomatosis with Polyangiitis Treatment Market by Drug Class
- 13.3.1 Market Overview
- 13.3.2 Steroids
- 13.3.3 Immunosuppressant
- 13.3.4 Others
- 13.4 United States Granulomatosis with Polyangiitis Treatment Market by Route of Administration
- 13.4.1 Market Overview
- 13.4.2 Oral
- 13.4.3 Intravenous
- 13.4.4 Others
- 13.5 United States Granulomatosis with Polyangiitis Treatment Market by Distribution Channel
- 13.5.1 Market Overview
- 13.5.2 Hospital Pharmacy
- 13.5.3 Retail Pharmacy
- 13.5.4 Online Pharmacy
- 14 EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market (2017-2032)
- 14.1 EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market Historical Value (2017-2023)
- 14.2 EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market Forecast Value (2024-2032)
- 14.3 EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market by Drug Class
- 14.3.1 Market Overview
- 14.3.2 Steroids
- 14.3.3 Immunosuppressant
- 14.3.4 Others
- 14.4 EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market by Route of Administration
- 14.4.1 Market Overview
- 14.4.2 Oral
- 14.4.3 Intravenous
- 14.4.4 Others
- 14.5 EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market by Distribution Channel
- 14.5.1 Market Overview
- 14.5.2 Hospital Pharmacy
- 14.5.3 Retail Pharmacy
- 14.5.4 Online Pharmacy
- 15 Japan Granulomatosis with Polyangiitis Treatment Market
- 15.1 Japan Granulomatosis with Polyangiitis Treatment Market Historical Value (2017-2023)
- 15.2 Japan Granulomatosis with Polyangiitis Treatment Market Forecast Value (2024-2032)
- 15.3 Japan Granulomatosis with Polyangiitis Treatment Market by Drug Class
- 15.3.1 Market Overview
- 15.3.2 Steroids

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.3.3□Immunosuppressant
- 15.3.4□Others
- 15.4□Japan Granulomatosis with Polyangiitis Treatment Market by Route of Administration
- 15.4.1□Market Overview
- 15.4.2□Oral
- 15.4.3□Intravenous
- 15.4.4□Others
- 15.5□Japan Granulomatosis with Polyangiitis Treatment Market by Distribution Channel
- 15.5.1□Market Overview
- 15.5.2□Hospital Pharmacy
- 15.5.3□Retail Pharmacy
- 15.5.4□Online Pharmacy
- 16□India Granulomatosis with Polyangiitis Treatment Market
- 16.1□India Granulomatosis with Polyangiitis Treatment Market (2017-2032) Historical Value (2017-2023)
- 16.2□India Granulomatosis with Polyangiitis Treatment Market (2017-2032) Forecast Value (2024-2032)
- 16.3□India Granulomatosis with Polyangiitis Treatment Market by Drug Class
- 16.3.1□Market Overview
- 16.3.2□Steroids
- 16.3.3□Immunosuppressant
- 16.3.4□Others
- 16.4□India Granulomatosis with Polyangiitis Treatment Market by Route of Administration
- 16.4.1□Market Overview
- 16.4.2□Oral
- 16.4.3□Intravenous
- 16.4.4□Others
- 16.5□India Granulomatosis with Polyangiitis Treatment Market by Distribution Channel
- 16.5.1□Market Overview
- 16.5.2□Hospital Pharmacy
- 16.5.3□Retail Pharmacy
- 16.5.4□Online Pharmacy
- 17□Regulatory Framework
- 17.1□Regulatory Overview
- 17.2□US FDA
- 17.3□EU EMA
- 17.4□INDIA CDSCO
- 17.5□JAPAN PMDA
- 17.6□Others
- 18□Patent Analysis
- 18.1□ Analysis by Type of Patent
- 18.2□ Analysis by Publication Year
- 18.3□ Analysis by Issuing Authority
- 18.4□ Analysis by Patent Age
- 18.5□ Analysis by CPC Analysis
- 18.6□ Analysis by Patent Valuation
- 18.7□ Analysis by Key Players
- 19□Clinical Trial Analysis
- 19.1□Analysis by Trial Registration Year

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 19.2□Analysis by Trial Status
- 19.3□Analysis by Trial Phase
- 19.4□Analysis by Therapeutic Area
- 19.5□Analysis by Geography
- 20□Grant Analysis
- 20.1□Analysis by Year
- 20.2□Analysis by Amount Awarded
- 20.3□Analysis by Issuing Authority
- 20.4□Analysis by Grant Product
- 20.5□Analysis by Funding Institute
- 20.6□Analysis by Departments
- 20.7□Analysis by Recipient Organization
- 21□Funding and Investment Analysis
- 21.1□Analysis by Funding Instances
- 21.2□Analysis by Type of Funding
- 21.3□Analysis by Funding Amount
- 21.4□Analysis by Leading Players
- 21.5□Analysis by Leading Investors
- 21.6□Analysis by Geography
- 22□Strategic Initiatives
- 22.1□ Analysis by Partnership Instances
- 22.2□ Analysis by Type of Partnership
- 22.3□ Analysis by Leading Players
- 22.4□ Analysis by Geography
- 23□Supplier Landscape
- 23.1□Market Share by Top 5 Companies
- 23.2□GlaxoSmithKline PLC
- 23.2.1□Financial Analysis
- 23.2.2□Product Portfolio
- 23.2.3□Demographic Reach and Achievements
- 23.2.4□Mergers and Acquisitions
- 23.2.5□Certifications
- 23.3□Bristol-Myers Squibb Company
- 23.3.1□Financial Analysis
- 23.3.2□Product Portfolio
- 23.3.3□Demographic Reach and Achievements
- 23.3.4□Mergers and Acquisitions
- 23.3.5□Certifications
- 23.4□Teva Pharmaceutical Industries Ltd .
- 23.4.1□Financial Analysis
- 23.4.2□Product Portfolio
- 23.4.3□Demographic Reach and Achievements
- 23.4.4□Mergers and Acquisitions
- 23.4.5□Certifications
- 23.5□Pfizer Inc .
- 23.5.1□Financial Analysis
- 23.5.2□Product Portfolio

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

23.5.3□Demographic Reach and Achievements

23.5.4□Mergers and Acquisition

23.5.5□Certifications

23.6□F. Hoffmann-La Roche Ltd

23.6.1□Financial Analysis

23.6.2□Product Portfolio

23.6.3□Demographic Reach and Achievements

23.6.4□Mergers and Acquisition

23.6.5□Certifications

23.7□Novartis AG

23.7.1□Financial Analysis

23.7.2□Product Portfolio

23.7.3□Demographic Reach and Achievements

23.7.4□Mergers and Acquisition

23.7.5□Certifications

23.8□Orion Corporation

23.8.1□Financial Analysis

23.8.2□Product Portfolio

23.8.3□Demographic Reach and Achievements

23.8.4□Mergers and Acquisition

23.8.5□Certifications

23.9□Amgen Inc .

23.9.1□Financial Analysis

23.9.2□Product Portfolio

23.9.3□Demographic Reach and Achievements

23.9.4□Mergers and Acquisition

23.9.5□Certifications

23.10□AstraZeneca PLC

23.10.1□Financial Analysis

23.10.2□Product Portfolio

23.10.3□Demographic Reach and Achievements

23.10.4□Mergers and Acquisition

23.10.5□Certifications

24□Granulomatosis with Polyangiitis Treatment Market - Distribution Model (Additional Insight)

24.1□ Overview

24.2□ Potential Distributors

24.3□ Key Parameters for Distribution Partner Assessment

25□Key Opinion Leaders (KOL) Insights (Additional Insight)

26□Payment Methods (Additional Insight)

26.1□Government Funded

26.2□Private Insurance

26.3□Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

market. The EMR team strives to make this section as comprehensive as possible.

****The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.**

Granulomatosis with Polyangiitis Treatment Market Report and Forecast 2024-2032

Market Report | 2024-07-19 | 200 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4999.00
	Five User License	\$5999.00
	Corporate License	\$6999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-06"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com